The United States eliminated indigenous wild polioviruses (WPVs) in 1979 and switched to inactivated poliovirus vaccine in 2000, which quickly ended all indigenous live poliovirus transmission. Continued WPV circulation and use of oral poliovirus vaccine globally allow for the possibility of reintroduction of these viruses. We evaluated the risk of a U.S. polio outbreak and explored potential vaccine needs for outbreak response.
Methods.
We synthesized information available on vaccine coverage, exemptor populations, and population immunity. We used an infection transmission model to explore the potential dynamics of a U.S. polio outbreak and potential vaccine needs for outbreak response, and assessed the impacts of heterogeneity in population immunity for two different subpopulations with potentially low coverage.
Results.
Although the risk of poliovirus introduction remains real, widespread transmission of polioviruses appears unlikely in the U.S., given high routine coverage. However, clusters of un- or underimmunized children might create pockets of susceptibility that could potentially lead to one or more paralytic polio cases. We found that the shift toward combination vaccine utilization, with limited age indications for use, and other current trends (e.g., decreasing proportion of the population with immunity induced by live polioviruses and aging of vaccine exemptor populations) might increase the vulnerability to poliovirus reintroduction at the same time that the ability to respond may decrease.
Conclusions.
The U.S. poliovirus vaccine stockpile remains an important resource that may potentially be needed in the future to respond to an outbreak if a live poliovirus gets imported into a subpopulation with low vaccination coverage.
References
1.
RoushSWMurphyTV; Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA2007;298:2155–63.
ThompsonKMTebbensRJ, Retrospective cost-effectiveness analyses for polio vaccination in the United States. Risk Anal2006;26:1423–40.
5.
Poliomyelitis prevention in the United States: Introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP) [published erratum appears in MMWR Morb Mortal Wkly Rep1997;46(8):183]. MMWR Recomm Rep 1997;46(RR-3):1–25.
6.
Impact of the sequential IPV/OPV schedule on vaccination coverage levels—United States, 1997. MMWR Morb Mortal Wkly Rep1998;47(47):1017–9.
7.
PrevotsDRBurrRKSutterRWMurphyTV; Advisory Committee on Immunization Practices. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep2000;49(RR-5):1–22.
8.
FDA licensure of diphtheria and tetanus toxoids and acellular pertussis adsorbed, hepatitis B (recombinant), and poliovirus vaccine combined, (PEDIARIX) for use in infants [published erratum appears in MMWR Morb Mortal Wkly Rep2003;52(16):379]. MMWR Morb Mortal Wkly Rep 2003;52(10):203–4.
AlexanderJPEhresmannKSewardJWaxGHarrimanKFullerS, Transmission of imported vaccine-derived poliovirus in an undervaccinated community in Minnesota. J Infect Dis2009;199:391–7.
11.
Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children. MMWR Morb Mortal Wkly Rep2008;57(39):1079–80.
12.
Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose. MMWR Morb Mortal Wkly Rep2008;57(39):1078–9.
13.
DeVriesASHarperJMurrayALexauCBahtaLChristensenJ, Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N Engl J Med2011;364:2316–23.
14.
JenkinsPCModlinJF, Decision analysis in planning for a polio outbreak in the United States. Pediatrics2006;118:611–8.
15.
AlexanderLBirkheadGGuerraFHelmsCHinmanAKatzS, Ensuring preparedness for potential poliomyelitis outbreaks: Recommendations for the US poliovirus vaccine stockpile from the National Vaccine Advisory Committee (NVAC) and the Advisory Committee on Immunization Practices (ACIP). Arch Pediatr Adolesc Med2004;158:1106–12.
DayanGHOrtega-SanchezIRLeBaronCWQuinliskMP; Iowa Measles Response Team. The cost of containing one case of measles: The economic impact on the public health infrastructure—Iowa, 2004. Pediatrics2005;116:e1–4.
18.
ParkerAAStaggsWDayanGHOrtega-SanchezIRRotaPALoweL, Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. N Engl J Med2006;355:447–55.
19.
ChenSYAndersonSKuttyPKLugoFMcDonaldMRotaPA, Health care-associated measles outbreak in the United States after an importation: Challenges and economic impact. J Infect Dis2011;203:1517–25.
20.
OnoratoIMModlinJFMcBeanMAThomsMLLosonskyGABernierRH, Mucosal immunity induced by enhanced-potency inactivated and oral polio vaccines. J Infect Dis1991;163:1–6.
21.
TebbensRJ DuintjerPallanschMAKewOMCáceresVMSutterRWThompsonKM, A dynamic model of poliomyelitis outbreaks: Learning from the past to help inform the future. Am J Epidemiol2005;162:358–72.
22.
TebbensRJPallanschMAAlexanderJPThompsonKM, Optimal vaccine stockpile design for an eradicated disease: Application to polio. Vaccine2010;28:4312–27.
23.
ThompsonKMTebbensRJ. DuintjerThe case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation. Medscape J Med2008;10:190.
24.
ThompsonKMTebbensRJ DuintjerPallanschMA, Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Anal2006;26:1541–56.
25.
SalmonDASotirMPanWKBergJLOmerSBStokleyS, Parental vaccine refusal in Wisconsin: A case control study. WMJ2009;108:17–23.
26.
SalmonDAMoultonLHOmerSBDeHartMPStokleySHalseyNA, Factors associated with refusal of childhood vaccines among parents of school-aged children: A case-control study. Arch Pediatr Adolesc Med2005;159:470–6.
27.
SmithPJSingletonJA, Vaccination coverage estimates for selected counties: Achievement of Healthy People 2010 goals and association with indices of access to care, economic conditions, and demographic composition. Public Health Rep2008;123:155–72.
PrevotsDRPascualFBAngelliliMLBraydenRIrigoyenMLarussaP, Population immunity to polioviruses among preschool children from four urban underserved low income communities, United States, 1997–2001. Pediatr Infect Dis J2004;23:1130–6.
30.
ChenRTHausingerSDajaniASHanflingMBaughmanALPallanschMA, Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States. JAMA1996;275:1639–45.
31.
FadenHDuffyLSunMShuffC.Long-term immunity to poliovirus in children immunized with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines. J Infect Dis1993;168:452–4.
32.
AbbinkFBuismanAMDoornbosGWoldmanJKimmanTGSpaendonckMA. Conyn-VanPoliovirus-specific memory immunity in seronegative elderly people does not protect against virus excretion. J Infect Dis2005;191:990–9.
33.
ModlinJFHalseyNAThomsMLMeschievitzCKPatriarcaPA, Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore Area Polio Vaccine Study Group. J Infect Dis1997;175Suppl 1:S228–34.
34.
StickleG.Observed and expected poliomyelitis in the United States, 1958–1961. Am J Public Health Nations Health1964;54:1222–9.
35.
ChinTDMarineWMHallECGravelleCRSpeersJF, Poliomyelitis in Des Moines, Iowa, 1959. The influence of Salk vaccination on the epidemic pattern and the spread of the virus in the community. Am J Hyg1961;74:67–94.
36.
MarineWMChinTDGravelleCR, Limitation of fecal and pharyngeal poliovirus excretion in Salk-vaccinated children. A family study during a type 1 poliomyelitis epidemic. Am J Hyg1962;76:173–95.
37.
GelfandHMLeBlancDRPotashLFoxJP, Studies on the development of natural immunity to poliomyelitis in Louisiana. IV. Natural infections with polioviruses following immunization with a formalin-inactivated vaccine. Am J Hyg1959;70:312–27.
38.
OostvogelPvan WijngaardenJvan der AvoortHGMuldersMNSpaendonckMA Conyn-VanRümkeH, Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992–93. Lancet1994;344:665–70.
SmithPJChuSYBarkerLE, Children who have received no vaccines: Who are they and where do they live?Pediatrics2004;114:187–95.
41.
SugermanDEBarskeyAEDeleaMGOrtega-SanchezIRBiDRalstonKJ, Measles outbreak in a highly vaccinated population, San Diego, 2008: Role of the intentionally undervaccinated. Pediatrics2010;125:747–55.
42.
National, state, and local area vaccination coverage among children aged 19–35 months—United States, 2007. MMWR Morb Mortal Wkly Rep2008;57(35):961–6.
TebbensRJ DuintjerPallanschMAKewOMSutterRWAylwardR BruceWatkinsM, Uncertainty and sensitivity analyses of a decision analytic model for post-eradication polio risk management. Risk Anal2008;28:855–76.
45.
BöttigerM.Polio immunity to killed vaccine: An 18-year follow-up. Vaccine1990;8:443–5.
46.
GlezenWPLambGABeldenEAChinTD, Quantitative relationship of preexisting homotypic antibodies to the excretion of attenuated poliovirus type 1. Am J Epidemiol1966;83:224–37.
47.
GlezenPWMcColloughRHLambGAChinTD, Quantitative relationship of preexisting homotypic antibodies to excretion of poliovirus types 1, 2, and 3 following the feeding of trivalent attenuated poliovirus vaccine. Am J Epidemiol1969;90:146–56.
48.
WehrlePFHagenFCarbonaroO.Transmission of polioviruses. II. Spread of attenuated poliovirus type III in a partially immunized school population. Pediatrics1961;27:755–61.
Public health dispatch: Measles epidemic—Majuro Atoll, Republic of the Marshall Islands, July 13–September 13, 2003. MMWR Morb Mortal Wkly Rep2003;52(37):888–9.
51.
Measles outbreak in a boarding school—Pennsylvania, 2003. MMWR Morb Mortal Wkly Rep2004;53(14):306–9.
Multistate measles outbreak associated with an international youth sporting event—Pennsylvania, Michigan, and Texas, August–September 2007. MMWR Morb Mortal Wkly Rep2008;57(7):169–73.
OmerSBPanWKHalseyNAStokleySMoultonLHNavarAM, Nonmedical exemptions to school immunization requirements: Secular trends and association of state policies with pertussis incidence. JAMA2006;296:1757–63.
58.
OmerSBSalmonDAOrensteinWADeHartMPHalseyN.Vaccine refusal, mandatory immunization, and the risks of vaccine-preventable diseases. N Engl J Med2009;360:1081–8.
59.
Updated recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination. MMWR Morb Mortal Wkly Rep2009;58(30):829–30.
60.
Diphtheria, tetanus, and pertussis: Recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep1991;40(RR-10):1–28.
61.
ShresthaSSWallaceGSMeltzerMI, Modeling the national pediatric vaccine stockpile: Supply shortages, health impacts, and cost consequences. Vaccine2010;28:6318–32.
